AI주식인사이트AI Stock Insight
C

에스바이오메딕스

304360KOSDAQ

47.0 / 100

Reference Date: 2026-09-08

Financial Score11.5 / 40
News Sentiment12.5 / 25
Momentum13.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 13.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

EsbioMedix is a biotech venture company specializing in the development and production of stem cell therapeutics, leveraging its platform technology to develop innovative drugs for various diseases. Its subsidiary, Estepham, focuses on manufacturing and selling anti-aging cosmetics and medical devices, capitalizing on the growing biopharmaceutical market trends and enhancing competitive advantages through differentiated technologies and products.

Number of Employees

52people

Average Salary

42.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
16.25Industry Average 1.200.0Point

13.5x industry avg (risky)

ROE
-40.30Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
72.79Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲12.6% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼22.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -58.4% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (27%)

Current 21,950Won52-week high 40,45052-week low 15,100
1-month return5.0Point

1m +13.73% (rising)

Volume trend5.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-31
  • Neutral주식등의대량보유상황보고서(일반)2026-08-25
  • Neutral반기보고서 (2026.06)2026-08-14
  • Neutral전환가액의조정 (제5회차)2026-08-13
  • Neutral전환사채(해외전환사채포함)발행후만기전사채취득 (제5회차)2026-08-13